Skip to main content

Clinical Trials Using Anti-FOLR1 Antibody-drug Conjugate

Review the clinical trials studying anti-folr1 antibody-drug conjugate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-12 of 12

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Status: Active
Location: 21 locations
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Status: Active
Location: 20 locations
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Active
Location: 17 locations
Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy for Folate Receptor Alpha Positive Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: 9 locations
Mirvetuximab Soravtansine for the Treatment of Folate Receptor-Alpha Positive Persistent or Recurrent Endometrial Cancer
Status: Active
Location: 7 locations
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Status: Active
Location: 8 locations
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Status: Active
Location: 6 locations
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Status: Active
Location: 5 locations
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Status: Active
Location: 7 locations
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Status: Active
Location: 9 locations
A Study of ZW191 in Participants With Solid Tumors
Status: Active
Location: 4 locations
Mirvetuximab Soravtansine and Olaparib for the Treatment of Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer with Positive Folate Receptor-Alpha Expression
Status: Active
Location: 4 locations